文献速递肝病

特利加压素治疗与失代偿期肝硬化患者多重耐药菌定植风险增加相关

Terlipressin therapy is associated with increased risk of colonisation with multidrug-resistant bacteria in patients with decompensated cirrhosis.
PubMed 文献 · Aliment Pharmacol Ther · 2024-02-27

巴塞罗那验证队列(n=129)显示特利加压素与随访期间多重耐药菌感染风险相关(p=0.017),另一多中心队列(n=203)粪便宏基因组测序显示抗生素灭活基因与特利加压素给药显著相关(p=0.001)。

要点

  • 特利加压素治疗与肝硬化急性失代偿/慢加急性肝衰竭患者多重耐药菌定植风险增加独立相关。
  • 多重耐药菌定植患者发生多重耐药菌感染的风险显著高于无定植者(p=0.0098)。
  • 验证队列中特利加压素与随访期间多重耐药菌感染风险相关,且抗生素灭活基因与特利加压素给药显著相关。

核心结论

  • 近期接受特利加压素治疗的急性失代偿或慢加急性肝衰竭患者多重耐药菌定植风险增加,而其他常用非抗生素合并用药影响可忽略。

研究设计与样本

  • 纳入巴塞罗那另一队列(n=129)进行验证。
  • 纳入第三个多中心队列(n=203),利用粪便宏基因组测序数据检测抗生素耐药基因。

主要发现

  • 97例(30%)患者存在多重耐药菌定植,其中35例(11%)发生多重耐药菌感染。
  • 多重耐药菌定植患者发生多重耐药菌感染的风险显著高于无定植者(p=0.0098)。
  • 除抗生素治疗(OR 2.91,95%CI 1.82-4.93,p<0.0001)外,既往14天内特利加压素治疗是唯一在两个队列中均与多重耐药菌定植独立相关的协变量(总体OR 9.47,95%CI 2.96-30.23,p<0.0001;倾向性评分匹配后OR 5.30,95%CI 1.22-23.03,p=0.011)。
  • 在第二队列中,既往特利加压素治疗是多重耐药菌定植的危险因素(OR 2.49,95%CI 0.911-6.823,p=0.075),并与随访期间多重耐药菌感染风险相关(p=0.017)。
  • 验证队列显示抗生素灭活基因与特利加压素给药显著相关(p=0.001)。

临床怎么用

  • 对接受特利加压素治疗的失代偿期肝硬化患者,应警惕多重耐药菌定植及后续感染风险,加强多重耐药菌筛查与监测。

局限性

  • 研究结果为观察性关联,未来需前瞻性试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with cirrhosis are susceptible to develop bacterial infections that trigger acute decompensation (AD) and acute-on-chronic liver failure (ACLF). Infections with multidrug-resistant organisms (MDRO) are associated with deleterious outcome. MDRO colonisation frequently proceeds MDRO infections and antibiotic therapy has been associated with MDRO colonisation. AIM: The aim of the study was to assess the influence of non-antibiotic medication contributing to MDRO colonisation. METHODS: Three hundred twenty-four patients with AD and ACLF admitted to the ICU of Frankfurt University Hospital with MDRO screening were included. Regression models were performed to identify drugs associated with MDRO colonisation. Another cohort (n = 129) from Barcelona was included to validate. A third multi-centre cohort (n = 203) with metagenomic sequencing data of stool was included to detect antibiotic resistance genes. RESULTS: A total of 97 patients (30%) were identified to have MDRO colonisation and 35 of them (11%) developed MDRO infection. Patients with MDRO colonisation had significantly higher risk of MDRO infection than those without (p = 0.0098). Apart from antibiotic therapy (odds ratio (OR) 2.91, 95%-confidence interval (CI) 1.82-4.93, p < 0.0001), terlipressin therapy in the previous 14 days was the only independent covariate associated with MDRO colonisation in both cohorts, the overall (OR 9.47, 95%-CI 2.96-30.23, p < 0.0001) and after propensity score matching (OR 5.30, 95%-CI 1.22-23.03, p = 0.011). In the second cohort, prior terlipressin therapy was a risk factor for MDRO colonisation (OR 2.49, 95% CI 0.911-6.823, p = 0.075) and associated with risk of MDRO infection during follow-up (p = 0.017). The validation cohort demonstrated that antibiotic inactivation genes were significantly associated with terlipressin administration (p = 0.001). CONCLUSIONS: Our study reports an increased risk of MDRO colonisation in patients with AD or ACLF, who recently received terlipressin therapy, while other commonly prescribed non-antibiotic co-medications had negligible influence. Future prospective trials are needed to confirm these results.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Mücke MM, Hernández-Tejero M, Gu W, et al. Terlipressin therapy is associated with increased risk of colonisation with multidrug-resistant bacteria in patients with decompensated cirrhosis. Aliment Pharmacol Ther. 2024. PMID: 38414095. doi:10.1111/apt.17899

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。